2018

Filter by Year:

Immuron and US Department of Defense look to develop silver bullet for gastro infections

16 July 2018

Biopharmaceutical company Immuron (ASX: IMC) is making significant territorial advances in its mission to develop and market a range of oral immunotherapeutics for the treatment of gut mediated pathogens.

US Defense finishes latest research on Immuron’s Travelan®

16 July 2018

The studies were designed to evaluate Travelan’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella bacterial infections. Travelan was shown to bind and was reactive to all strains of bacteria tested.

Immuron reports positive clinical study results in the fight against fatty liver disease

8 March 2018

Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis (NASH) clinical study. The primary objective of the study was to evaluate the safety and efficacy of IMM-124E.

Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%

8 March 2018

Top-line data showed treatment with IMM-124E (bovine colostrum) produced a statistically significant reduction in serum lipopolysaccharide (LPS) levels compared to placebo. LPS is associated with the progression of NASH.

Immuron’s shares surge on demonstrating proof of concept for liver drug candidate

8 March 2018

Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

Results in: IMC’s lead drug reduces major factor in liver inflammation

8 March 2018

Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharide (LPS) levels compared to placebo; statistically significant reduction in mean serum ALT in patients with elevated pre-treatment AL

Blockbuster Results from IMC’s NASH Liver Therapy Trials

8 March 2018

Today, IMC is setting a new standard as far as ‘positive developments’ go, topline results show significant improvement in liver injury and a significant reduction in blood levels of LPS — a known mediator of liver inflammation in patients with NASH.